US equities |
NVDA $239.58 ▲+2.41% SPCX $169.72 ▲+6.77% MU $1,061.36 ▼-1.26% TSLA $380.52 ▲+2.68% SNDK $1,695.12 ▼-1.45% MSFT $528.55 ▲+2.13% INTC $116.43 ▼-2.43% META $743.96 ▲+2.18%
FinancialContent

Qiagen N.V. Common Shares (NY:QGEN)

45.87 +1.12 (+2.50%)
Delayed Quote Updated: 3:22 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Qiagen N.V. Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
QIAGEN and DiaSorin widen access to latent TB testing in the U.S. with FDA approval of QuantiFERON®-TB Gold Plus assay on LIAISON® XS
From QIAGEN N.V.
Via Business Wire
News headline image
Qiagen Says Its COVID-19 PCR Tests Can Detect The New South African Variant ↗
Qiagen N.V. (NYSE:QGEN) announced that its polymerase c... 
Via Benzinga
Rising Test Accuracy Standards Needed as On-Site Demand for Covid-19 Testing Increases
FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 9, 2021 – USA News Group – After the launch of US President Joe Biden’s pushing of mandatory vaccination/testing in the... 
Via FinancialNewsMedia
News headline image
QIAGEN Commits to Reduce Carbon Emissions by Setting Science-Based Target to Reach Net Zero by 2050
From QIAGEN N.V.
Via Business Wire
News headline image
Qiagen, Becton Dickinson Settle Patent Infringement Lawsuit For $53M ↗
Qiagen N.V. (NYSE: QGEN) settled with Becton Dickinson & Co (NYSE: BDX) a patent infringement lawsuit related to Qiagen's NeuMoDx 96 and NeuMoDx... 
Via Benzinga
Topics Intellectual Property Lawsuit
News headline image
QIAGEN and BD Settle Patent Infringement Lawsuit
From QIAGEN N.V.
Via Business Wire
News headline image
Qiagen NV (QGEN) Q3 2021 Earnings Call Transcript ↗
QGEN earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Qiagen Clocks 17% Increase In Non-COVID Product Sales; Raises FY21 Guidance ↗
Qiagen N.V.'s (NYSE: QGEN) Q3 revenues grew 11% Y/Y to $535 million (+10% at constant exchange rates), well above the consensus of $434.97 million. Non-COVID... 
Via Benzinga
News headline image
QIAGEN Reports Strong Results for Third Quarter and First Nine Months Of 2021
From QIAGEN N.V.
Via Business Wire
News headline image
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics... 
Via Benzinga
Topics Retirement
News headline image
QIAGEN expands QIAstat-Dx testing menu with respiratory four-plex panel that differentiates between flu, RSV and SARS-CoV-2
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Strengthens UK Footprint With Move to New Manchester Facilities
From QIAGEN N.V.
Via Business Wire
News headline image
Earnings Scheduled For November 3, 2021 ↗
Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
News headline image
QIAGEN N.V. to Release Results for Q3 2021 and First Nine Months of 2021
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Launches Novel QIAreach QuantiFERON-TB Tuberculosis Test for High-Burden Regions
From QIAGEN N.V.
Via Business Wire
News headline image
Qiagen Secures DoD Contract To Boost Production Capacity For NeuMoDx ↗
Qiagen NV (NYSE: QGEN) won a U.S. government contract to increase the production capacity for consumables used on its NeuMoDx 96 and 288 integrated PCR testing... 
Via Benzinga
News headline image
QIAGEN Receives U.S. Department of Defense Contract to Further Expand Production Capacity for NeuMoDx
From QIAGEN N.V.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021 ↗
Upgrades According to Roth Capital, the prior rating for Ring Energy Inc (AMEX: 
Via Benzinga
Big Changes Coming to Covid Testing in Response to Rising Demand Under Latest Mandates
Via FinancialNewsMedia
Why New Covid-19 Test Supplies Will Be Needed Soon in Wake of US President’s New OSHA Mandates
Via FinancialNewsMedia
News headline image
QIAGEN to Enter the DAX – Germany’s Leading Stock Market Index
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Reaches Milestone With Its Kits Used to Process More Than Three Billion Biological Samples to Date
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN and GT Molecular Collaborate to Offer a Complete SARS-CoV-2 Wastewater Detection Solution Based on QIAcuity Digital PCR Technology
From QIAGEN N.V.
Via Business Wire
News headline image
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,... 
Via Benzinga
News headline image
Qiagen Inks Companion Diagnostic Development, Technology-Licensing Deal With OncXerna ↗
Qiagen NV (NYSE: QGEN) and OncXerna Therapeutics have signed a master agreement to develop a next-generation sequencing (NGS) companion diagnostic for... 
Via Benzinga
News headline image
QIAGEN and OncXerna Therapeutics Sign Licensing and Master Companion Diagnostic Agreements
From QIAGEN N.V.
Via Business Wire
News headline image
Qiagen's COVID-19 Antigen Test Gets FDA Emergency Use Approval ↗
The FDA has granted emergency use authorization (EUA) to Qiagen N.V.'s (NYSE: QGEN) QIAreach SARS CoV-2 Antigen Test. The rapid, portable test can detect... 
Via Benzinga
News headline image
QIAGEN receives U.S. FDA emergency use authorization for rapid portable test that can analyze over 30 samples per hour for SARS-CoV-2 antigen
From QIAGEN N.V.
Via Business Wire
News headline image
3 Must-Own Healthcare Stocks For Your Portfolio ↗
Healthcare stocks have had a steady run so far this year, with the industry’s growth prospects—based on ongoing digitization to revolutionize and increase demand—motivating investors. Thus, we believe... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9 10 Next >